ARC
VNDA icon

Absolute Return Capital’s Vanda Pharmaceuticals VNDA Stock Holding History

Absolute Return Capital’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-14,277
Closed -$231K – 949
2014
Q2 		$231K Buy
+14,277
New +$190K ﹤0.01% 990

Other funds holding VNDA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
SCA
Signpost Capital Advisors New York $34.2M AUM 5.08% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Absolute Return Capital's VNDA Position: Q3 2014 in Review

Absolute Return Capital sold out of Vanda Pharmaceuticals (VNDA) in Q3 2014, closing a stake of 14,277 shares — an estimated $231K sold.

Absolute Return Capital first reported a position in VNDA in Q2 2014 and held it in 1 quarter. The position peaked at $231K in Q2 2014. 101 funds tracked by Wall St. Rank hold VNDA as of Q3 2014.

  • Absolute Return Capital reported no remaining Vanda Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
  • Absolute Return Capital sold 14,277 Vanda Pharmaceuticals shares in Q3 2014, an estimated $231K.
  • Absolute Return Capital first reported a position in Vanda Pharmaceuticals in Q2 2014 and held it in 1 quarter.
  • Absolute Return Capital's Vanda Pharmaceuticals position peaked at $231K in Q2 2014.
  • 101 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2014.

Based on Absolute Return Capital's 13F filing for Q3 2014, filed 14 Nov 2014.